Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01642004 · ClinicalTrials.gov registry record · Phase 3
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 272
- Enrollment target
NCT01642004 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 272 participants.
The verdict
NCT01642004, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 272 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.
Interventions
- DRUG Docetaxel
- BIOLOGICAL Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2012-10-16 |
| Est. Completion | 2021-08-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01642004
The ClinicalTrials.gov registry entry for NCT01642004 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01642004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01642004 about?
NCT01642004 is a clinical study titled "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)". The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.
What is the current status of trial NCT01642004?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 272 participants. The study started on 2012-10-16. Estimated completion is 2021-08-16.
What interventions are being tested in trial NCT01642004?
The interventions under investigation include: Docetaxel (DRUG), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01642004?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.